Hims & Hers Faces Mounting Pressure from Data Breach and Legal Challenges

Telehealth firm Hims & Hers grapples with a data security incident, ongoing class action lawsuit, and terminated Novo Nordisk partnership, pressuring its stock and operations.

The telehealth company Hims & Hers is navigating a complex array of operational and legal difficulties. A recent data security incident, an ongoing class action lawsuit, and a terminated partnership with pharmaceutical giant Novo Nordisk are collectively weighing on the firm, with the pressure evident in its stock performance.

Financial Performance and Market Sentiment

For the 2025 fiscal year, Hims & Hers reported revenue of $2.35 billion and earnings per share of $0.51. The company's shares closed at $19.14 on April 2, marking a single-day decline of 3.53 percent. Its current market capitalization stands at approximately $4.2 billion. Investment firm TD Cowen maintained a "Hold" rating on the equity at the end of March, setting a price target of $23.00. Investors are awaiting the next quarterly results, scheduled for release on May 4, 2026, for clearer signs of whether these accumulating challenges are impacting the financial statements.

Security Incident Compounds Existing Troubles

These financial figures arrive amidst a fresh crisis. Between February 4 and 7, 2026, unauthorized individuals gained access to an external customer support system through a social engineering attack. The breach resulted in the theft of personal information, including names and email addresses contained within support tickets. Hims & Hers formally notified the California Attorney General's office of the event on April 2 and has begun alerting impacted customers.

The company has emphasized that no medical records or confidential doctor-patient communications were compromised in this incident. The precise number of affected individuals has not yet been disclosed. In response, several law firms are investigating the potential for class action litigation related to the data exposure.

Ongoing Legal Scrutiny Intensifies

This new security problem exacerbates an already contentious legal environment. The law firm Kahn Swick & Foti is conducting an investigation into company executives concerning allegations of withheld information and potentially misleading statements about business performance. This probe is connected to the sudden dissolution of a partnership with Novo Nordisk in June 2025.

The Danish pharmaceutical leader terminated the agreement, accusing Hims & Hers of violating regulations concerning the distribution of compounded medications and engaging in misleading marketing practices. A recent motion by Hims & Hers to dismiss the resulting lawsuit was denied in court, allowing the legal proceedings to continue. This combination of new and existing legal threats presents a significant overhang for the telehealth provider.